Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study

Abstract Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. Methods N...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. Lin, Hans Garmo, Mieke Van Hemelrijck, Jan Adolfsson, Pär Stattin, Björn Zethelius, Danielle Crawley
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Prostate cancer diagnosis Gonadotropin-releasing hormone agonists Diabetes Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/99c33006006c4a96a64c57146bddbb8f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:99c33006006c4a96a64c57146bddbb8f
record_format	dspace
spelling	oai:doaj.org-article:99c33006006c4a96a64c57146bddbb8f2021-11-28T12:27:37ZExploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study10.1186/s12885-021-08941-y1471-2407https://doaj.org/article/99c33006006c4a96a64c57146bddbb8f2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08941-yhttps://doaj.org/toc/1471-2407Abstract Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. Methods Nationwide population-based cohort study in the Swedish National Diabetes Register and Prostate Cancer data Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. Worsening diabetes control was the primary outcome, defined as: 1) HbA1c rose to 58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of antidiabetic drugs or switch to insulin. We also combined all above definitions. Cox proportional hazards regression was used to analyze the association. Results There were 5714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free men with T2DM with similar baseline characteristics. Diabetes control was worse in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13–1.34) as well as compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39–1.80), when we defined the worsening control of diabetes by combining all definitions above. Conclusion Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The findings highlight the need to closely monitor diabetes control in men with T2DM and PCa starting GnRH.E. LinHans GarmoMieke Van HemelrijckJan AdolfssonPär StattinBjörn ZetheliusDanielle CrawleyBMCarticleProstate cancer diagnosisGonadotropin-releasing hormone agonistsDiabetesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Prostate cancer diagnosis Gonadotropin-releasing hormone agonists Diabetes Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Prostate cancer diagnosis Gonadotropin-releasing hormone agonists Diabetes Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 E. Lin Hans Garmo Mieke Van Hemelrijck Jan Adolfsson Pär Stattin Björn Zethelius Danielle Crawley Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
description	Abstract Background Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. Methods Nationwide population-based cohort study in the Swedish National Diabetes Register and Prostate Cancer data Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. Worsening diabetes control was the primary outcome, defined as: 1) HbA1c rose to 58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of antidiabetic drugs or switch to insulin. We also combined all above definitions. Cox proportional hazards regression was used to analyze the association. Results There were 5714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free men with T2DM with similar baseline characteristics. Diabetes control was worse in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13–1.34) as well as compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39–1.80), when we defined the worsening control of diabetes by combining all definitions above. Conclusion Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The findings highlight the need to closely monitor diabetes control in men with T2DM and PCa starting GnRH.
format	article
author	E. Lin Hans Garmo Mieke Van Hemelrijck Jan Adolfsson Pär Stattin Björn Zethelius Danielle Crawley
author_facet	E. Lin Hans Garmo Mieke Van Hemelrijck Jan Adolfsson Pär Stattin Björn Zethelius Danielle Crawley
author_sort	E. Lin
title	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
title_short	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
title_full	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
title_fullStr	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
title_full_unstemmed	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
title_sort	exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/99c33006006c4a96a64c57146bddbb8f
work_keys_str_mv	AT elin exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT hansgarmo exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT miekevanhemelrijck exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT janadolfsson exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT parstattin exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT bjornzethelius exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy AT daniellecrawley exploringtheassociationbetweenuseofgonadotropinreleasinghormonesagonistsandprostatecancerdiagnosisperseanddiabetescontrolinmenwithtype2diabetesmellitusanationwidepopulationbasedcohortstudy
_version_	1718407971846750208

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study

Ejemplares similares